NCT06932068招募中2 期
Safety and Efficacy of Iparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy for the Treatment of HER2-Negative, Low PD-L1 Expressing, Unresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: A Phase II Single-Arm Trial
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 77
- 试验地点
- 27
- 主要终点
- progression-free survival (PFS)
研究概览
简要总结
This is single - arm study to explore the safety and efficacy of iparomlimab and tuvonralimab (QL1706) combined with chemotherapy for treating her2-negative, low PD-L1 expressing, unresectable or metastatic gastric/gastroesophageal junction adenocarcinoma
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Aged 18-75 years, gender is not limited;
- •Pathologically confirmed locally advanced gastric or gastroesophageal junction adenocarcinoma that is inoperable or has distant metastasis;
- •HER2-negative by immunohistochemistry (IHC);
- •low PD-L1 expression status (CPS < 5);
- •Has at least 1 measurable lesion as determined by RECIST 1.1;
- •No systematic treatment in the past, or the patient has received neoadjuvant/adjuvant chemotherapy, but the disease progresses or relapses more than 6 months after the end of treatment;
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0-1;
- •Adequate organ function;
- •The life expectancy is at least 3 months;
- •Willing to join the study and signed an informed consent form (ICF) with good compliance and cooperation in follow-up.
排除标准
- •Allergic to any trial drug and its excipients, or serious allergy history, or contraindication of the trial drug;
- •Cardiovascular and cerebrovascular events that are not well controlled;
- •Has received systematic treatment with Chinese patent medicine or immunomodulatory drugs (including thymosin, interferon, interleukin, except for local use for ascites control) before the first administration within 2 weeks;
- •Have a history of interstitial lung disease, non-infectious pneumonia, pulmonary fibrosis, acute lung disease, or systemic disease with poor control (including but not limited to diabetes, hypertension, etc.);
- •Have a history of active immune deficiency or autoimmune diseases, including HIV positive test, or have other acquired or congenital immune deficiency diseases, or have a history of organ transplantation or autoimmune diseases;
- •Severe chronic or active infection requires systemic antibacterial, antifungal or antiviral treatment, including tuberculosis infection.Have a history of active tuberculosis infection ≥ 1 year before recruitment should also be excluded, unless proved has been completed appropriate treatment;
- •Brain metastasis or leptomeningeal metastasis;
- •Clinically significant pleural effusion, pericardial effusion or ascites should be drained for many times within 2 weeks before the first administration of the trial drug;
- •Has a second clinically detectable primary malignant tumor at the time of recruitment, or there were other malignant tumors in the past 5 years (except for fully treated skin basal cell carcinoma or cervical carcinoma in situ);
- •Any major surgery was performed ≤ 28 days before the first trial drug administration;
- •History of allogeneic stem cell transplantation or organ transplantation;
- •Duodenal ulcer, ulcerative colitis, intestinal obstruction and other gastrointestinal diseases at present; or other conditions that may cause gastrointestinal bleeding or perforation judged by the researchers; or history of intestinal perforation or fistula, but has not recovered after surgical treatment;
- •Live vaccine was inoculated within 4 weeks (inclusive) before the first administration of the trial drug, not including seasonal influenza vaccines but intranasal vaccine.
- •Has other factors that may lead to the forced termination of this trial according to the judgment of the investigator, such as other serious diseases (including psychological and mental diseases) requiring combined treatment, serious laboratory examination abnormalities, and family or social factors, which may affect the safety of the subject, or the collection of data and samples;
- •Participating in other therapeutic clinical studies or using research instruments within 4 weeks before the first administration;
- •Others conditions do not meet the inclusion according to the judgment of the investigator.
研究组 & 干预措施
QL1706 + XELOX chemotherapy
Experimental
Iparomlimab and Tuvonralimab+XELOX
干预措施: Iparomlimab and Tuvonralimab (QL1706) (Drug)
QL1706 + XELOX chemotherapy
Experimental
Iparomlimab and Tuvonralimab+XELOX
干预措施: Oxallplation (Drug)
QL1706 + XELOX chemotherapy
Experimental
Iparomlimab and Tuvonralimab+XELOX
干预措施: Capectitabine Tablets (Drug)
结局指标
主要结局
progression-free survival (PFS)
时间窗: 12 months after the last subject participating in
The time from the starting date of study drug to the date of first documentation of disease progression or death, whichever occurs first (per RECIST 1.1).
次要结局
- overall survival (OS)(12 months after the last subject participating in)
- objective response rate (ORR)(6 months after the last subject participating in)
- Safety (adverse event)(Up to approximately 2 years)
- duration of response (DOR)(12 months after the last subject participating in)
- disease control rate (DCR)(12 months after the last subject participating in)
研究者
Lian Liu, MD, PHD
Director of Department of Oncology
Qilu Hospital of Shandong University
研究点 (27)
Loading locations...
相似试验
招募中
2 期
Perioperative Study of Iparomlimab and Tuvonralimab in Resectable NSCLCNCT06897046Cancer Institute and Hospital, Chinese Academy of Medical Sciences90
Unknown
2 期
Efficacy and Safety of Toripalimab (JS001) Combined With Pemetrexed and Anlotinib for Patients With T790M Positive Non-Small Cell Lung Cancer After Osimertinib ResistanceIIIb/IV NSCLC With T790M Positive Mutations Failed to Osimertinib TherapyNCT04316351Guangzhou Institute of Respiratory Disease60
Unknown
2 期
Exploring the Safety and Effectiveness of Toripalimab Combined With Neoadjuvant Radiotherapy and Chemotherapy in the Locally Advanced Esophageal Squamous Cell CarcinomaLocally Advanced Esophageal Squamous Cell CarcinomaNCT04888403The First Affiliated Hospital of Zhengzhou University45
终止
2 期
A Study to Evaluate the Efficacy and Safety of Toripalimab Injection in the Treatment of Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Who Have Failed at Least Two Prior Lines of Therapy and Are Positive Specific MarkersRecurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Who Have Failed at Least Two Prior Lines of TherapyNCT04603040Shanghai Junshi Bioscience Co., Ltd.17
Unknown
3 期
Toripalimab in Combination With Lenvatinib and TACE for Conversion Therapy in Patients With Potentially Resectable HCCHepatocellular CarcinomaNCT05056337Shanghai Zhongshan Hospital220